Abstract
Background
We investigated the clinical efficacy and the prolongation of survival with combination therapy of estramustine phosphate (EMP) and endocrine therapy in untreated patients with progressive prostate cancer.
Methods
We randomly divided 57 patients with untreated stage D prostate cancer into two groups, an endocrine monotherapy group and a group receiving combination treatment, consisting of endocrine therapy plus EMP. Treatment was continued until deterioration.
Results
There were no significant differences in the improvement rating for subjective/objective symptoms or in progression-free survival between the two groups. However, overall survival was significantly prolonged in the combination therapy group (log-rank test, P = 0.0394; generalized Wilcoxon's test, P = 0.0145). In particular, overall survival was significantly prolonged, compared to that in the endocrine monotherapy group, in patients in the combination therapy group who were less than 74 years old, those with a performance status (PS) of 1 to 3, a pretreatment prostate-specific antigen (PSA) level of more than 20 ng/ml, moderately or poorly differentiated carcinoma, or a partial response (PR) based on the PSA level 12 weeks after the start of treatment. There was no significant difference in the incidence of side effects between the combination therapy and the endocrine monotherapy groups.
Conclusion
A combination of EMP with endocrine therapy may be useful for initial treatment in younger patients (aged 73 or younger) and in patients at high risk of progressive prostate cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
InstitutionalAuthorNameProstate Cancer Trialists Collaborative group (2000) ArticleTitleMaximum androgen blockade in advanced prostate cancer: an overview of the randomized trials Lancet 355 1491–1499 Occurrence Handle10.1016/S0140-6736(00)02163-2
Y Kubota T Nakada K Imai et al. (1995) ArticleTitleChemo-endocrine therapy in patients with stage D2 prostate cancer Prostate 26 50–54 Occurrence Handle7845867 Occurrence Handle1:STN:280:ByqC2cfkt1U%3D
IN Frank (1983) Urologic and male genital cancer P Rubin (Eds) Clinical oncology American Cancer Society New York 198–200
MS Soloway SW Hardeman D Hickey et al. (1988) ArticleTitleStratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan Cancer 61 195–202 Occurrence Handle3334948 Occurrence Handle1:STN:280:BieD2sbos1E%3D Occurrence Handle10.1002/1097-0142(19880101)61:1<195::AID-CNCR2820610133>3.0.CO;2-Y
InstitutionalAuthorNameJapanese Urological Association, The Japanese Society of Pathology (1992) General rule for clinical and pathological studies on prostate cancer EditionNumber2nd ed Kanehara Tokyo, Japan
M Usami (1997) ArticleTitleProstate cancer: selection of treatment Curr Ther 15 62–67
JT Issacs N Kyprianou (1987) ArticleTitleDevelopment of androgen-independent tumor cells and their implication for the treatment of prostatic cancer Urol Res 15 133–138
JT Issacs (1984) ArticleTitleThe timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer Prostate 5 1–17
N Kadohama RY Kirdani GP Murphy et al. (1978) ArticleTitleEstramustine phosphate: metabolic aspects related to its action in prostatic cancer J Urol 119 234–239 Occurrence Handle633484 Occurrence Handle1:STN:280:CSeC3szhsVM%3D
S Saito J Nakashima Y Nakajima et al. (2001) ArticleTitleClinical efficacy of leuprolide acetate and combined treatment with estramustine for advanced prostate cancer Jpn J Urol 92 682–693 Occurrence Handle1:STN:280:DC%2BD38%2FktVamuw%3D%3D
I Takenaka S Soramoto S Kagawa et al. (2001) ArticleTitleMulticenter randomized clinical trial comparing Estracyt mono-therapy with combined androgen blockade therapy (CAB) in the treatment of advanced prostate cancer Nishinihon J Urol 63 1–9
H Matsuda K Nonomura S Nagamori et al. (1995) ArticleTitleClinicopathological evaluation of etoposide or estramustine phosphate in castrated patients with advanced prostatic cancer Jpn J Urol 86 1530–1537 Occurrence Handle1:STN:280:BymD2srgtF0%3D
M Noguchi S Noda M Yoshida et al. (2004) ArticleTitleChemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist Int J Urol 11 103–109 Occurrence Handle14706014 Occurrence Handle1:CAS:528:DC%2BD2cXislalsL0%3D Occurrence Handle10.1111/j.1442-2042.2004.t01-1-00748.x
Roessner M, de Wit R, Tannock IF et al. (2005) Prostate-specific antigen (PSA) response as a surrogate endpoint for overall survival (OS): analysis of the TAX 327 Study comparing docetaxel plus prednisone with mitoxantrone plus prednisone in advanced prostate cancer. Proceedings of ASCO annual meeting, 2005. Abstract No. 4554, p 391
BR Konety JA Eastham VE Reuter et al. (2004) ArticleTitleFeasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study J Urol 171 709–713 Occurrence Handle14713792 Occurrence Handle10.1097/01.ju.0000108122.36893.5a
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/s10147-006-0641-y.
About this article
Cite this article
Hoshi, S., Yamaguchi, O., Fujioka, T. et al. A randomized comparative study of endocrine monotherapy and a combination of estramustine phosphate with the endocrine therapy in patients with untreated stage D prostate cancer. Int J Clin Oncol 11, 303–308 (2006). https://doi.org/10.1007/s10147-006-0563-8
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10147-006-0563-8